Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus

Abstract Introduction Acute bacterial skin and skin structure infections (ABSSSIs) remain among the most common infectious processes seen in the clinical setting. For patients with complicated ABSSSIs deemed to require intravenous antibiotics, vancomycin remains the mainstay therapy. Ceftaroline has...

Full description

Bibliographic Details
Main Authors: Kimberly C. Claeys, Evan J. Zasowski, Trang D. Trinh, Anthony M. Casapao, Jason M. Pogue, Nitin Bhatia, Ryan P. Mynatt, Suprat S. Wilson, Crystal Arthur, Robert Welch, Robert Sherwin, Wasif Hafeez, Donald P. Levine, Keith S. Kaye, George Delgado, Christopher A. Giuliano, Robert Takla, Colleen Rieck, Leonard B. Johnson, Kyle P. Murray, James Gordon, Kate Reyes, Pamela Hartman, Susan L. Davis, Michael J. Rybak
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-03-01
Series:Infectious Diseases and Therapy
Subjects:
Acute bacterial skin and skin structure infection
Ceftaroline
Methicillin-resistant S. aureus
Vancomycin
Online Access:http://link.springer.com/article/10.1007/s40121-019-0242-5

Internet

http://link.springer.com/article/10.1007/s40121-019-0242-5

Similar Items